Catalent (CTLT) Announces Acquisition of OTC Softgel Maker Accucaps Industries
- Wall Street set to open flat as investors test rally
- Western Digital (WDC) Raises Q2 Outlook
- Biotech, Pharma Stocks Weaker Amid Trump Comments on Lower Drug Prices
- Oil slips on doubts output cut will end global glut
- Pre-Open Stock Movers 12/07: (EMKR) (PLAY) (WDC) Higher; (SIGM) (AVAV) (BLUE) Lower (more...)
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Catalent, Inc. (Catalent) (NYSE: CTLT) announced that it has agreed to acquire Accucaps Industries Limited (Accucaps), the Canada-based developer and manufacturer of Over-the-Counter (OTC), high potency and conventional pharmaceutical softgels. Financial details of the transaction have not been disclosed.
The acquisition, which is subject to Canadian governmental approval, will substantially complement Catalent’s global OTC and prescription pharmaceutical softgel capabilities and capacity with the addition of a portfolio of products supplied to pharmaceutical companies in North America, and two state-of-the-art facilities offering integrated softgel development, manufacturing and packaging, strengthening Catalent’s ability to offer customers turnkey solutions.
Commenting on the acquisition, Dr. Aris Gennadios, Catalent’s President of Softgel Technologies, said, “Significant investments already made by Accucaps align well with Catalent’s own strategic goals, to offer our customers access to more products, capacity, and integrated solutions for differentiated products and better treatments.”
Upon completion of the acquisition, Accucaps’ over 500 employees, at its two facilities in Windsor and Strathroy, Ontario, will join Catalent’s global network of 11 Softgel Technologies facilities. The Accucaps facilities house sizeable blistering, bottling and other packaging capabilities, as well as high-potency prescription softgel development and manufacturing expertise that are complementary to Catalent’s.
Catalent RP Scherer Softgel is a global leader in innovative oral and topical softgel technologies for the pharmaceutical, consumer health, and cosmetics markets. Its softgel technologies are proven to solve complex bioavailability and formulation challenges, and are preferred in a wide range of consumer health and pharmaceutical product categories. Catalent leverages more than 80 years of experience in softgel formulation, development and manufacturing, as well as its proactively developed products, to help customers bring products to market faster. With a variety of unique, innovative technologies, and highly versatile, most preferred dose forms, Catalent has a wide variety of solutions to meet its customers’ needs.
Catalent was advised by RBC Capital Markets.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Curtiss-Wright (CW) to Acquire Teletronics Technology in $233M Cash Deal
- Fidelity National Financial (FNF) Board Approves Plan to Distribute Black Knight Financial (BKFS) Shares
- Linde Chairman Said to Pitch Praxair's (PX) Merger Proposal to Board - Bloomberg
Create E-mail Alert Related CategoriesCorporate News, Management Comments, Mergers and Acquisitions
Related EntitiesRBC Capital, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!